Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
$0.08
-12.5%
$0.08
$0.08
$1.73
$2.44M2.011.54 million shs4.31 million shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$3.08
+3.5%
$3.09
$2.51
$4.86
$9.35M-0.66134,603 shs133,676 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$1.30
-1.8%
$1.87
$0.87
$10.80
$6.24M0.478,291 shs13,328 shs
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
$8.52
-6.9%
$7.38
$5.00
$17.40
$10.74M0.2775,518 shs5,537 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
0.00%0.00%0.00%-13.41%-92.93%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
+3.85%+3.85%-8.62%+14.89%-32.50%
Orgenesis Inc. stock logo
ORGS
Orgenesis
-6.17%-13.46%-41.67%-27.25%+132,399,900.00%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-0.33%-2.86%+28.90%+42.54%-30.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
0.92 of 5 stars
3.50.00.00.00.00.00.0
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
1.7738 of 5 stars
3.52.00.00.00.01.70.6
Orgenesis Inc. stock logo
ORGS
Orgenesis
1.8408 of 5 stars
0.05.00.04.40.00.00.0
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
4.1918 of 5 stars
3.75.00.04.80.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
3.00
Buy$5.506,607.32% Upside
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
3.00
Buy$10.00225.20% Upside
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
3.33
Buy$90.00956.34% Upside

Current Analyst Ratings Breakdown

Latest AWH, KPRX, ORGS, and SNSE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$100.00
5/1/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
$9.18M0.27N/AN/A($0.23) per share-0.36
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$16.02M0.58$1.33 per share2.31$8.58 per share0.36
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K9.42N/AN/A($6.58) per share-0.20
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/A$30.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
-$16.69M-$0.98N/AN/A-165.07%N/A-267.23%8/11/2025 (Estimated)
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$3.60M-$2.90N/AN/AN/AN/A-42.82%-32.18%8/8/2025 (Estimated)
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36MN/A0.00N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$30.16M-$23.00N/AN/AN/AN/A-66.72%-57.10%8/5/2025 (Estimated)

Latest AWH, KPRX, ORGS, and SNSE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$6.20N/AN/AN/AN/AN/A
5/9/2025Q1 2025
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A
5/6/2025Q1 2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$4.20-$5.40-$1.20-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
$1.041,268.29%N/AN/A N/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
N/A
0.75
0.70
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/A
5.14
5.14
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/A
6.82
6.82

Institutional Ownership

CompanyInstitutional Ownership
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
12.19%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
76.97%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
10.50%

Insider Ownership

CompanyInsider Ownership
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
4.30%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
0.05%
Orgenesis Inc. stock logo
ORGS
Orgenesis
5.66%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
23.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
11029.76 million16.92 millionNo Data
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
103.04 million3.04 millionNot Optionable
Orgenesis Inc. stock logo
ORGS
Orgenesis
1504.80 million4.53 millionNo Data
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
401.26 million968,000Not Optionable

Recent News About These Companies

Sensei Rockets on FY ’24 Results
Sensei Rockets on FY ’24 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aspira Women's Health stock logo

Aspira Women's Health NASDAQ:AWH

$0.08 -0.01 (-12.49%)
As of 04/16/2025

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Kiora Pharmaceuticals stock logo

Kiora Pharmaceuticals NASDAQ:KPRX

$3.08 +0.11 (+3.54%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$1.30 -0.02 (-1.81%)
As of 02:32 PM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Sensei Biotherapeutics stock logo

Sensei Biotherapeutics NASDAQ:SNSE

$8.52 -0.63 (-6.89%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.